Literature DB >> 14624761

Epitopes of calreticulin recognised by IgA autoantibodies from patients with hepatic and coeliac disease.

Daniel Sánchez1, Ludmila Tucková, Thomas Mothes, Wolfgang Kreisel, Zdenek Benes, Helena Tlaskalová-Hogenová.   

Abstract

Calreticulin (CRT) was identified as a frequent target of serum autoantibodies (Ab) in various diseases, but anti-CRT Ab of IgA isotype were described only in coeliac (CLD) and some hepatic diseases. Employing ELISA with recombinant CRT we found significantly higher (P<0.001) levels of IgA anti-CRT Ab in sera of patients with primary biliary cirrhosis (PBC) (77.6+/-8.9 AU/mean+/-SE), autoimmune hepatitis (AIH) (105.1+/-9.2 AU) and alcoholic liver cirrhosis (ALC) (193.5+/-21.0 AU) relative to healthy controls (38.6+/-2.0 AU). The levels of IgG anti-CRT Ab in sera of patients with PBC (59.5+/-3.4 AU), AIH (89.7+/-7.9 AU) and ALC (86.4+/-6.2 AU) were also significantly increased (P<0.001) when compared with controls (38.5+/-2.1 AU). Pepscan technique with decapeptides of CRT (each overlapping by eight amino acids) revealed antigenic epitopes of this molecule recognised by IgA Ab of almost all tested patients-KGKNVLINKD and QVKSGTIFDNFL. We also identified disease specific antigenic epitopes on CRT molecule, predominantly recognised by IgA Ab of patients suffering from a particular disease: GGYVKLFPNS and YVKLFPNSLD in AIH (83%, 92% of patients), GLQTSQDARF and EQRLKEEEED in CLD (both 75%) and ASKPEDWDER in ALC (67%). Identification of disease specific CRT epitopes contributes to clarification of autoreactivity against this molecule.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14624761     DOI: 10.1016/s0896-8411(03)00137-9

Source DB:  PubMed          Journal:  J Autoimmun        ISSN: 0896-8411            Impact factor:   7.094


  7 in total

1.  Contribution of humoral immune responses to the antitumor effects mediated by anthracyclines.

Authors:  D Hannani; C Locher; T Yamazaki; V Colin-Minard; M Vetizou; L Aymeric; S Viaud; D Sanchez; M J Smyth; P Bruhns; G Kroemer; L Zitvogel
Journal:  Cell Death Differ       Date:  2013-06-07       Impact factor: 15.828

2.  Anti-calreticulin immunoglobulin A (IgA) antibodies in refractory coeliac disease.

Authors:  D Sánchez; L Palová-Jelínková; J Felsberg; M Simsová; A Pekáriková; B Pecharová; I Swoboda; T Mothes; C J J Mulder; Z Benes; H Tlaskalová-Hogenová; L Tucková
Journal:  Clin Exp Immunol       Date:  2008-07-11       Impact factor: 4.330

3.  Celiac disease markers in patients with liver diseases: a single center large scale screening study.

Authors:  Pavel Drastich; Eva Honsová; Alena Lodererová; Marcela Jarešová; Aneta Pekáriková; Iva Hoffmanová; Ludmila Tučková; Helena Tlaskalová-Hogenová; Julius Spičák; Daniel Sánchez
Journal:  World J Gastroenterol       Date:  2012-11-21       Impact factor: 5.742

4.  Calreticulin is a B cell molecular target in some gastrointestinal malignancies.

Authors:  A Pekáriková; D Sánchez; L Palová-Jelínková; M Simsová; Z Benes; I Hoffmanová; P Drastich; I Janatková; T Mothes; H Tlaskalová-Hogenová; L Tucková
Journal:  Clin Exp Immunol       Date:  2009-12-17       Impact factor: 4.330

5.  Characterization of a Synovial B Cell-Derived Recombinant Monoclonal Antibody Targeting Stromal Calreticulin in the Rheumatoid Joints.

Authors:  Elisa Corsiero; Lucas Jagemann; Mauro Perretti; Costantino Pitzalis; Michele Bombardieri
Journal:  J Immunol       Date:  2018-07-25       Impact factor: 5.422

Review 6.  Celiac Disease and Liver Disorders: From Putative Pathogenesis to Clinical Implications.

Authors:  Iva Hoffmanová; Daniel Sánchez; Ludmila Tučková; Helena Tlaskalová-Hogenová
Journal:  Nutrients       Date:  2018-07-12       Impact factor: 5.717

Review 7.  Contribution of Infectious Agents to the Development of Celiac Disease.

Authors:  Daniel Sánchez; Iva Hoffmanová; Adéla Szczepanková; Věra Hábová; Helena Tlaskalová-Hogenová
Journal:  Microorganisms       Date:  2021-03-06
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.